Dr. Kutlar has served Augusta University since 1982 where he has made major contributions to clinical care, basic science, clinical research, and educational activities. He is a graduate of Ankara University Medical School in Ankara, Turkey. He completed his residency and one year as chief resident and fellowship in internal medicine/hematology at Istanbul University Medical School in Istanbul, Turkey.

Following clinical and research fellowships in Turkey, a Special Fellow in the Department of Laboratory Hematology at the Cleveland Clinic in Cleveland, and as a Research Fellow at the Medical College of Georgia, he joined the faculty at the Medical College of Georgia as an Associate Professor in 1992. Dr. Kutlar practices hematology with a focus on benign hematology and is an active member of the American Society of Hematology. He has served and continues to serve on state and NIH committees.

Dr. Kutlar is currently the Co-PD/PI of the multi-institutional National Institute of Minority Health and Health Disparities Southeastern Exploratory Sickle Cell Center of Excellence as well as the Co-PD/PI of the National Heart, Lung, and Blood Institute’s Excellence in Hemoglobinopathies Research Award. He has completed more than 20 industry sponsored trials and federally funded projects, is working on two investigator initiated projects, and has brought to Augusta University an excess of nine million dollars in research support. Dr. Kutlar has 200 original articles, two book chapters, and 177 abstract presentations.

Representative Publications:

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)

Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder